Robert Giugliano is currently an Associate Physician in the Cardiovascular Division at the Brigham and Women’s Hospital and Assistant Professor in Medicine at Harvard Medical School. He graduated summa cum laude and phi beta kappa, majoring in mathematics at Dartmouth College, and received his medical degree at Harvard Medical School. Dr Giugliano completed his internship, residency, and chief residency in Los Angeles at Cedars-Sinai Medical Center, an affiliate hospital of UCLA, and then returned to Boston as a cardiology fellow at the Massachusetts General Hospital. In 1996, Dr Giugliano joined the Brigham and Women’s Hospital as a Research Fellow in Medicine working with the Thrombolysis in Myocardial Infarction (TIMI) Study Group under the direction of Eugene Braunwald, and completed a masters of science degree in epidemiology at the Harvard School of Public Health. In 1997, he joined the faculty in the cardiovascular division of the Brigham and Women’s Hospital and has served as the principal investigator for 8 multicenter clinical trials as part of the TIMI Study Group.

 

His areas of research interest include novel antithrombotic and fibrinolytic agents for acute coronary syndromes (ACS), lipid-lowering therapies, and the assessment of outcomes in patients with ACS. He has authored over 100 articles and 25 editorials/book chapters, and has given hundreds of lectures nationally and internationally. Dr Giugliano is the principal TIMI investigator for the EARLY ACS trial on use of eptifibatide in high-risk non–ST-elevation–ACS. He is also a coinvestigator and member of the operations committee for the IMPROVE-IT trial comparing ezetimibe/simvastatin to simvastatin in 10,000 patients post ACS. Dr Giugliano was the principal investigator at Brigham and Women’s for a number of additional trials, including the AVANTE-GARDE-TIMI 43, PROVE IT-TIMI 22, A2Z, and TIMI 11b studies, and has served on numerous Data Safety Monitoring Boards, clinical endpoint committees, and Holter/ECG Core Laboratories. Dr Giugliano also continues to participate in ongoing research projects with the Massachusetts General Hospital Unstable Angina/Myocardial Infarction Research Group and the MGH Coronary Clinical Trials Group.